PriceTargets.com logo

Aphria - APHA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$15.38 As of 05/7/2021 01:00 AM ET
+0 (0.00%)
Get New Aphria Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APHA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aphria in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.38.

This chart shows the closing price for APHA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Aphria. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2021Standpoint ResearchReiterated RatingHold$18.00High
4/13/2021Pi FinancialDowngradeBuy ➝ NeutralHigh
4/13/2021CIBCLower TargetOutperform$28.00 ➝ $23.00High
4/8/2021Alliance Global PartnersBoost TargetPositive ➝ Buy$20.00 ➝ $26.00Low
4/6/2021Stifel NicolausBoost TargetHold$15.50 ➝ $22.00High
2/22/2021CIBCBoost TargetOutperform$18.00 ➝ $28.00High
2/16/2021Cantor FitzgeraldBoost TargetOverweight$26.00 ➝ $32.50Low
2/4/2021Stifel NicolausReiterated RatingHold$4.50Low
1/19/2021Stifel NicolausBoost TargetHold$9.80 ➝ $15.50High
1/15/2021CIBCBoost TargetOutperform$12.50 ➝ $18.00High
1/15/2021Cantor FitzgeraldBoost TargetOverweight$11.75 ➝ $26.00Low
1/15/2021Alliance Global PartnersBoost TargetBuy$12.00 ➝ $20.00High
1/15/2021BMO Capital MarketsBoost TargetPositive ➝ Market Perform$7.00 ➝ $15.00High
12/17/2020CIBCBoost TargetOutperform$9.00 ➝ $12.50High
12/17/2020Stifel NicolausDowngradeBuy ➝ HoldHigh
12/16/2020Alliance Global PartnersBoost TargetBuy$9.00 ➝ $12.00High
11/6/2020CIBCBoost TargetOutperform$8.00 ➝ $9.00Medium
10/16/2020CIBCBoost TargetOutperform$7.50 ➝ $8.00Low
10/16/2020Cantor FitzgeraldLower TargetOverweight$15.50 ➝ $11.75High
10/5/2020Cantor FitzgeraldBoost TargetOverweight$12.50 ➝ $15.50High
8/17/2020CIBCUpgradeNeutral ➝ Outperform$7.50Low
7/30/2020Pi FinancialReiterated RatingBuyLow
7/30/2020CIBCBoost TargetNeutral$6.00 ➝ $7.50Medium
7/27/2020Cantor FitzgeraldBoost TargetOverweight$10.50 ➝ $11.00High
7/15/2020Alliance Global PartnersReiterated RatingBuy$9.00Medium
7/13/2020Stifel NicolausUpgradeHold ➝ Buy$5.30 ➝ $8.00High
5/8/2020Cantor FitzgeraldBoost TargetOverweight$9.50 ➝ $9.85Low
4/16/2020Eight CapitalUpgradeBuyMedium
4/16/2020Stifel NicolausBoost TargetHold$4.50 ➝ $5.30Medium
4/16/2020Bank of AmericaBoost TargetBuy$5.00 ➝ $7.00Medium
4/16/2020CIBCBoost TargetNeutral$6.00 ➝ $7.00High
4/15/2020Alliance Global PartnersReiterated RatingBuy$11.00 ➝ $9.00High
4/15/2020Cantor FitzgeraldLower TargetOverweight$9.30 ➝ $9.00Medium
4/1/2020Cantor FitzgeraldLower TargetOverweight$11.50 ➝ $9.30High
3/19/2020Bank of AmericaUpgradeNeutral ➝ BuyHigh
3/9/2020Stifel NicolausInitiated CoverageHold$4.50Medium
1/21/2020Alliance Global PartnersInitiated CoverageBuy$11.00Medium
1/20/2020Jefferies Financial GroupReiterated RatingBuy$10.30Medium
1/14/2020CIBCUpgradeUnderperform ➝ Neutral$7.00High
1/13/2020Bank of AmericaInitiated CoverageNeutralHigh
11/5/2019Cantor FitzgeraldInitiated CoverageOverweight$10.40Medium
10/16/2019CIBCReiterated RatingSell$6.50High
10/15/2019Jefferies Financial GroupSet TargetBuy$8.30Low
10/15/2019Pi FinancialSet TargetBuy$9.00Low
7/26/2019CIBCDowngradeNeutral ➝ Sector UnderperformHigh
5/24/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$11.00High
(Data available from 4/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aphria logo
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Read More

Today's Range

Now: $15.38
Low: $15.38
High: $15.38

50 Day Range

MA: $15.48
Low: $13.14
High: $18.37

52 Week Range

Now: $15.38
Low: $2.78
High: $32.29

Volume

N/A

Average Volume

21,826,307 shs

Market Capitalization

$4.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Aphria?

The following sell-side analysts have issued reports on Aphria in the last twelve months:
View the latest analyst ratings for APHA.

What is the current price target for Aphria?

0 Wall Street analysts have set twelve-month price targets for Aphria in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aphria in the next year.
View the latest price targets for APHA.

What is the current consensus analyst rating for Aphria?

Aphria currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for APHA.

What other companies compete with Aphria?

Other companies that are similar to Aphria include Halozyme Therapeutics, Krystal Biotech, CRISPR Therapeutics, Bausch + Lomb and Glaukos. Learn More about companies similar to Aphria.

How do I contact Aphria's investor relations team?

Aphria's physical mailing address is 98 TALBOT STREET W., LEAMINGTON A6, N8H 1M8. The company's listed phone number is (844) 427-4742 and its investor relations email address is [email protected]. The official website for Aphria is aphriainc.com. Learn More about contacing Aphria investor relations.